サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159200

筋緊張性ジストロフィー治療薬の世界市場（2022年～2028年）

Myotonic Dystrophy Drug Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 130 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
筋緊張性ジストロフィー治療薬の世界市場（2022年～2028年）
出版日: 2022年09月22日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の筋緊張性ジストロフィー治療薬の市場規模は、予測期間中に7.6%のCAGRで成長すると予想されています。革新的な疾患治療薬の発売、研究開発の活発化、筋緊張性ジストロフィーの発症率の上昇は、市場の成長を後押しすると推測されます。

当レポートでは、世界の筋緊張性ジストロフィー治療薬市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • Sanofi, S.A.
  • Lupin Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場セグメンテーション

  • 世界の筋緊張性ジストロフィー治療薬市場：薬剤タイプ別
    • 抗筋緊張薬
    • 非ステロイド系抗炎症薬（NSAID）
    • 抗うつ薬
    • その他
  • 世界の筋緊張性ジストロフィー治療薬市場：投与経路別
    • 経口
    • 静脈内
  • 世界の筋緊張性ジストロフィー治療薬市場：流通チャネル別
    • オフライン薬局
    • オンライン薬局

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • ANI Pharmaceuticals Inc.
  • BioMarin Pharmaceutical IncBioMarin
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • C.H. Boehringer Sohn AG & Ko. KG
  • ECHEMI Technology Co. Ltd.
  • F. Hoffman-La Roche Ltd.
  • Ionic Pharmaceuticals, Inc.
  • Lannett Co, Inc
  • Mallinckrodt PharmaceuticalsMallinckrodt
  • Marina Biotech Inc.
  • Pfizer Inc.
  • Pharma Circle LLC
  • Sanofi Apotex Pharmaceutical Holdings Inc.
  • Sun Pharmaceuticals Industries Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
  • 2. GLOBAL ANTI-MYOTONIC DRUGSMARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 3. GLOBAL NSAIDS MYOTONIC DYSTROPHY DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 4. GLOBAL ANTI DEPRESSANTS MYOTONIC DYSTROPHY DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 5. GLOBAL OTHERS MYOTONIC DYSTROPHY DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 6. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
  • 7. GLOBAL MYOTONIC DYSTROPHY DRUG BY ORAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 8. GLOBAL MYOTONIC DYSTROPHY DRUG BY INTRAVENOUS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 9. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
  • 10. GLOBAL ONLINE MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 11. GLOBAL OFFLINE MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2022 - 2028 ($ MILLION)
  • 12. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2022 - 2028 ($ MILLION)
  • 13. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
  • 14. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
  • 15. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
  • 16. NORTH AMERICAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
  • 17. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
  • 18. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
  • 19. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
  • 20. EUROPEAN MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
  • 21. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
  • 22. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
  • 23. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
  • 24. ASIA-PACIFIC MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)
  • 25. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022 - 2028 ($ MILLION)
  • 26. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022 - 2028 ($ MILLION)
  • 27. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2022 - 2028 ($ MILLION)
  • 28. REST OF THE WORLD MYOTONIC DYSTROPHY DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022 - 2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL MYOTONIC DYSTROPHY DRUG MARKET, 2022 - 2028($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL MYOTONIC DYSTROPHY DRUG MARKET BY SEGMENT, 2022 - 2028($ MILLION)
  • 3. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY DRUG TYPE, 2022 VS 2028 (%)
  • 4. RECOVERY OF GLOBAL MYOTONIC DYSTROPHY DRUG MARKET, 2022-2028 (%)
  • 5. GLOBAL ANTI-MYOTONIC DRUGSMARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 6. GLOBAL NSAIDS MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 7. GLOBAL ANTIDEPRESSANTS MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 8. GLOBAL OTHERS MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 9. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY ROUTE OF ADMINISTRATION, 2022 VS 2028 (%)
  • 10. GLOBAL MYOTONIC DYSTROPHY DRUG BY ORAL MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 11. GLOBAL MYOTONIC DYSTROPHY DRUG BY INTRAVENOUS MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 12. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2028 (%)
  • 13. GLOBAL ONLINE MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 14. GLOBAL OFFLINE MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 15. GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SHARE BY GEOGRAPHY, 2022 VS 2028 (%)
  • 16. US GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 17. CANADA GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 18. UK GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 19. FRANCE GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 20. GERMANY GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 21. ITALY GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 22. SPAIN GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 23. REST OF EUROPE GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 24. INDIA GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 25. CHINA GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 26. JAPAN GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 27. REST OF ASIA-PACIFIC GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
  • 28. REST OF THE WORLD GLOBAL MYOTONIC DYSTROPHY DRUG MARKET SIZE, 2022 - 2028($ MILLION)
目次
Product Code: OMR2026178

Global Myotonic dystrophy drug Market Size, Share & Trends Analysis Report by Drug Type (Sodium Channel Blockers, NSAIDs, Antidepressants, and Others), by Route of Administration (Oral, Intravenous), and by Distribution Channel( Online Pharmacies, Offline Pharmacies) Forecast 2022-2028

The global myotonic dystrophy drug market is anticipated to grow at a substantial CAGR of 7.6% during the forecast period. Myotonic dystrophy refers to a series of long-term hereditary illness that affects the body muscle. Muscle atrophy develops with time as a symptom. The global myotonic dystrophy drug market is growing due to the launch of innovative disease therapies and increased research and developments. Additionally, a rise in the incidence of myotonic dystrophy along with the demand for effective treatment with innovative drugs is estimated to boost the market growth. Wider coverage in the health insurance sector and incidences of chronic illnesses such as arthritis, neurovascular conditions will help the myotonic dystrophy market to grow in the forecast period.

The global myotonic dystrophy drug market is segmented based on the drug type, route of administration, and distribution channel. Based on the drug type, the market is segmented into anti-myotonic drugs , NSAIDs, antidepressants, and others.. Based on the route of administration, the market is sub-segmented into oral and intravenous. Based on the distribution channel, the market is sub-segmented into the online pharmacy and offline pharmacies.

Regionally, the global myotonic dystrophy drug market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to hold the major share and dominate the global myotonic dystrophy drug market in 2021. Increasing research & development activities, along with an increase in the number of clinical trials for muscular dystrophy drugs have boosted the regional market growth. The Asia-Pacific region is expected to be the fastest growing region. This is generally due to the various awareness programs from the Parental Drug Association and the trending use of effervescent tablets in recent decades. Various research and development of key market players in this region to treat different diseases by developing novel drugs are also helping the market to hold a prominent share in this region.

The major companies serving the global myotonic dystrophy drug market include ANI Pharmaceuticals, Inc., Lupin Ltd., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., and many more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, On May 3, 2021, ICREA Researcher Professor and head of the Biosensors for Bioengineering group at IBEC developed a three-dimensional model for myotonic dystrophy using bioengineering technique and patient cells.

 

Research Methodology

The market study of the global myotonic dystrophy drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalogue.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global myotonic dystrophy drug market Research and Analysis by Drug Type
  • Global myotonic dystrophy drug market Research and Analysis by Route of Administration
  • Global myotonic dystrophy drug market Research and Analysis by Distribution Channel

The Report Covers:

  • Comprehensive Research Methodology of the global myotonic dystrophy drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global myotonic dystrophy drug market.
  • Insights about market determinants that are stimulating the global myotonic dystrophy drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global Myotonic Dystrophy Drug Market
  • Recovery Scenario of Global Myotonic Dystrophy Drug Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Sanofi, S.A.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Lupin Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Novartis AG
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Teva Pharmaceutical Industries Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Myotonic Dystrophy Drug Market by Drug Type
    • 4.1.1. Anti-Myotonic Drugs
    • 4.1.2. Nonsterodial Anti-Inflammatories (NSAIDs)
    • 4.1.3. Antidepressants
    • 4.1.4. Others
  • 4.2. Global Myotonic Dystrophy Drug Market by Route of Administration
    • 4.2.1. Oral
    • 4.2.2. Intravenous
  • 4.3. Global Myotonic Dystrophy Drug Market by Distribution channel
    • 4.3.1. Offline Pharmacies
    • 4.3.2. Online Pharmacies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. ANI Pharmaceuticals Inc.
  • 6.2. BioMarin Pharmaceutical IncBioMarin
  • 6.3. Boehringer Ingelheim International GmbH
  • 6.4. Bristol-Myers Squibb Co.
  • 6.5. C.H. Boehringer Sohn AG & Ko. KG
  • 6.6. ECHEMI Technology Co. Ltd.
  • 6.7. F. Hoffman- La Roche Ltd.
  • 6.8. Ionic Pharmaceuticals, Inc.
  • 6.9. Lannett Co, Inc
  • 6.10. Mallinckrodt PharmaceuticalsMallinckrodt
  • 6.11. Marina Biotech Inc.
  • 6.12. Pfizer Inc.
  • 6.13. Pharma Circle LLC
  • 6.14. Sanofi Apotex Pharmaceutical Holdings Inc.
  • 6.15. Sun Pharmaceuticals Industries Ltd.